Can Tc99 mebrofenine scintigraphy predict liver failure after major hepatectomy. An observational multicentre study in patients undergoing hepatectomy for benign or malignant liver tumors. (MULTIMEBRO)
A randomised controlled trial of Rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS- Cardiovascular OutcoMes for People using Anticoagulation StrategieS) - Long-Term Open-Label Extension (LTOLE).
A phase 1b, randomized, double-blind, placebo-controlled, multi-center, single-ascending dose study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of DS-1040b when added to standard of care anticoagulation therapy in subjects with acute submassive pulmonary embolism
Characterization of patients following acute venous thromboembolism (VTE) and safety and effectiveness of dabigatran etexilate (DE) in the treatment and secondary prevention of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) in comparison to vitamin K antagonist (VKA) in routine clinical practice
An international, multicenter, randomized, double-blind, placebo controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures
Recurrent venous thromboembolism risk stratification evaluation. Validation of the "Men and HERDOO2" - a clinical decision rule to identify patients with "unprovoked" venous thromboembolism who can discontinue anticoagulants after six months of treatment
A double-blind, placebo controlled, multicentre, clinical Trial to investigate the efficacy and safety of 12 months of therapy with inhaled PROMIXIN® (colistimethate sodium) in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)”
A randomized, blinded, parallel group, multi-center dose- finding study, to assess the efficacy, safety and tolerability of different doses of Tobramycin inhalation powder in patients with Non-Cystic Fibrosis Bronchiectasis and pulmonary P. aeruginosa infection
A phase IIb, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and intermediate or high probability of group 3 pulmonary hypertension.
A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment
A 12-week, double-blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment.
« Long term observational, prospective study to collect in a real-life setting data on the retention, effectiveness, safety, treatment pattern, quality of life (QoL), and efficiency of secukinumab in adult patients with moderate to severe plaque psoriasis. ».
A phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of INCB054828 in subjects with advabced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 translocations who failed previous therapy